To treat blood cancers and other disorders for which no other treatment was effective, hematopoietic cell transplantation (HCT) has been utilised for over 40 years. 1 More than 800,000 patients have had allogeneic or autologous transplants since the first three successful allogeneic HCT instances in 1968. 2 More than 60,000 people a year throughout the globe benefit from these therapies.
Because to modifications in selection criteria, refinement of pretransplantation conditioning protocols, and advancements in prevention and treatment of graft-versus-host disease (GVHD) and infection since the early 1970s, mortality in the first 100 days after HCT has reduced. Human leukocyte antigen–identical sibling donors currently have survival rates of more than 60% after one year. 2 The number of 5-year survivors has surpassed 150,000 and is expected to continue to rise as a result of lower early mortality and increased usage of HCT.
For at least ten years following the surgery, mortality rates among HCT patients are greater than those in the general population.
3–7 Chronic GVHD, infection, and other post-transplant problems are the primary causes of late mortality, as are recurrence of a second malignancy, GVHD treatment failure, and transplant-related complications. When it comes to life expectancy after a bone marrow transplant, the cumulative impact of late problems were examined in this research.
Hematologic malignancies and other disorders may be cured by hematopoietic cell transplantation, however this therapy can potentially result in long-term problems. The long-term consequences of hematopoietic cell transplantation on life expectancy have not been examined in previous investigations.
Regression analysis using age as the time axis was used to examine variables that could influence death rates and to assess their impact on life expectancy. With the typical proper filtering, we were able to handle entries that were staggered by age.